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Inherently disparate cell growth and division, which are intimately coupled through adelicate network of intra-
cellular and extracellular signaling, require ribosomal biogenesis. A number of events imparting instability to
ribosomal biogenesis can cause nucleolar stress. In response to this stress, several ribosomal proteins bind
to MDM2 and block MDM2-mediated p53 ubiquitination and degradation, resulting in p53-dependent cell
cycle arrest. By doing so, the ribosomal proteins play a crucial role in connecting deregulated cell growth
with inhibition of cell division. The ribosomal protein-MDM2-p53 signaling pathway provides a molecular
switch that may constitute a surveillance network monitoring the integrity of ribosomal biogenesis.Introduction
Cell growth (increase in cell size) and cell division (increase in cell
number) are two separable yet interconnected aspects of cell
behavior in all organisms (Conlon and Raff, 1999). Cell growth is
dominant and rate limiting for cell division (Hartwell, 1971). Block-
ing cell growth of cultured mammalian cells by reagents that
inhibit ribosomal biogenesis leads to arrest of the cell cycle,
usually in theG1phase (Pardee,1989).Deregulationof themolec-
ular mechanisms controlling cell growth results in cells of altered
size and leads to developmental errors and a variety of patholog-
ical conditions, including cancer (Ruggero and Pandolfi, 2003).
It is clear that mutations in genes involved in cell division
control often contribute to cancer development, and one prom-
inent example is the p53 tumor suppressor. In response to
cellular stress, p53 is activated to induce cell cycle arrest, senes-
cence, or apoptosis. Mutations in p53 inactivating p53’s function
are frequently found in both familial and sporadic human
cancers. More than 50% of human cancers harbor mutations
in TP53; in most of the remaining cancers, the p53 pathway is
otherwise inactivated, such as through overproduction of the
p53 inhibitor MDM2 (murine double minute 2, and also HDM2
for its human ortholog) (Toledo andWahl, 2006). While disruption
of normal cell cycle control is an established route to cancer, it is
more controversial whether an increase in cell growth on its own
can initiate or promote cancer development (Ruggero and Pan-
dolfi, 2003). Overall, the mechanisms that link cell growth with
cell division are poorly understood (Sulic et al., 2005b). However,
recent studies have begun offering some clues for associating
the MDM2-p53 feedback loop with the sophisticated mecha-
nisms involving ribosomal biogenesis.
The MDM2-p53 feedback loop is regulated in response to
a multitude of cytotoxic and genotoxic stressors. One of these
stressors is called nucleolar stress (also known as ribosomal
stress) (Rubbi and Milner, 2003). In principle, ribosome biogen-
esis is an essential cellular process that involves three funda-mental steps: coordinated expression of ribosomal RNA (rRNA)
and ribosomal proteins (RPs), processing of rRNA, and assembly
of the 40S and 60S ribosome subunits in the nucleolus (Perry,
2007). The 40S and 60S subunits are then exported from the
nucleolus, through the nucleoplasm, into the cytoplasm for
80S ribosome assembly and protein synthesis (Perry, 2007).
Perturbation of any step in this process is thought to lead to
nucleolar stress, triggering specific binding of several RPs to
MDM2, which inhibits MDM2’s E3 ubiquitin ligase function
toward p53, leading to p53 stabilization and activation (Lind-
strom et al., 2007a). For instance, expression of a dominant-
negative mutant of Bop1 involved in rRNA processing can inhibit
ribosomal biogenesis and elicit p53 activation (Pestov et al.,
2001). Likewise, reduced production of individual RPs can also
prompt p53 activation. In vivo inactivation of RPS6 activates
a p53-dependent checkpoint response in thymocytes (Sulic
et al., 2005a) or in embryonic fibroblast cells during gastrulation
(Panic et al., 2006). Similar to the mammalian system, deficiency
of several RPs in zebrafish also initiates p53-dependent cell
growth arrest and apoptosis (Chakraborty et al., 2009; Danilova
et al., 2008). Hence, these findings suggest an important role for
the nucleolus as a cellular stress sensor in addition to as the
workshop for ribosomal biogenesis. They also place p53 as
a key molecule in the center of the signaling pathway sensing
nucleolar stress and ribosomal malfunction. This review aims
to illustrate recent progress toward understanding this newly
acknowledged, yet under-studied, RP-MDM2-p53 signaling
pathway. (Readers are referred to recent reviews for other extra-
ribosomal functions of RPs [Warner and McIntosh, 2009] and
downstream functions [Vousden and Prives, 2009] and regula-
tions [Kruse and Gu, 2009] of p53.).
The Ribosomal Protein-MDM2-p53 Pathway
In order to better illustrate the RP-MDM2-p53 pathway, it is
necessary to briefly revisit what we have learned regarding theCancer Cell 16, November 3, 2009 ª2009 Elsevier Inc. 369
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cellular stresses. MDM2 regulates p53 primarily in two ways:
(1) MDM2 binds directly to p53, thereby ‘‘masking’’ p53’s trans-
activation domain from access to the basal transcriptional
machinery (Oliner et al., 1993), and (2) MDM2 acts as an E3 ubiq-
uitin ligase for p53,mediating the conjugation of ubiquitins to p53
and subsequent proteasomal degradation (Haupt et al., 1997;
Honda et al., 1997; Kubbutat et al., 1997). BecauseMDM2 itself
is a transcriptional target of p53 (Barak et al., 1993; Wu et al.,
1993) and deletion of Tp53 completely rescues the lethality of
Mdm2 knockout mice (Jones et al., 1995; Montes de Oca Luna
et al., 1995), the primary physiological function of MDM2 is thus
to serve as a negative feedback ‘‘knot’’ for p53, and therefore
unhitching this MDM2 knot becomes critical for p53 activation
by various stresses.
Increasing evidence has supported the notion that various
stresses can activate distinct cellular signaling pathways that
lead to the suppression of MDM2 activity and activation of p53
(Vogelstein et al., 2000; Vousden and Lu, 2002). For instance,
DNA damage caused by genotoxic chemicals and ionizing or
ultraviolet radiation triggers the activation of the ATM-Chk2 or
ATR-Chk1 kinase cascades that leads to phosphorylation of
both MDM2 and p53, blocking their functional or physical inter-
actions (Appella and Anderson, 2001; Prives, 1998). Also, biolog-
ical and oncogenic signals, such as viral infection or overexpres-
sion of cellular oncogenes, induce the expression of the tumor
suppressor ARF, which in turn binds to MDM2 and inhibits its
activity (Sherr, 2006; Zhang and Xiong, 2001). Moreover,
different types of stress have been shown to trigger a number
of posttranslational modifications, including acetylation, sumoy-
lation, methylation, and neddylation, of p53 and/or MDM2 result-
ing in p53 activation (reviewed by Brooks and Gu, 2003; Dai
et al., 2006a; Huang and Berger, 2008; Melchior and Hengst,
2002; Prives and Manley, 2001).
Recently, a new type of stress signal generated by disrupting
ribosomal biogenesis and mediated by several RPs has been
shown to inhibit MDM2 and activate p53. Ribosomal biogenesis
can be disrupted by serum starvation, depletion of nucleotides,
agents such as actinomycin D or 5-Fluorouracil, malfunction of
nucleolar proteins involved in ribosome biogenesis (such as
the dominant-negative mutant Bop1) (Pestov et al., 2001), inhibi-
tion of B23 (also known as nucleophosmin) activity by ARF
(Itahana et al., 2003), and reduction of RPS6 (Fumagalli et al.,
2009; Volarevic et al., 2000); all of these have been shown to
generate nucleolar stress that signals to p53. This allows cells
to halt proliferation under unhealthy and poor ribosomal biogen-
esis conditions. Although MDM2 was previously shown to
interact with 5S rRNA and RPL5 (Marechal et al., 1994), the func-
tional meaning of the interaction had not been realized until
recently when several RPs, including RPL11 (Lohrum et al.,
2003; Zhang et al., 2003), RPL23 (Dai et al., 2004; Jin et al.,
2004), and RPL5 (Dai and Lu, 2004), were found to activate
p53 through their interactions with MDM2.
Previously, RPL5 was shown to participate in MDM2 nuclear
export (Roth et al., 1998). It was thought that the p53-MDM2
complex might ‘‘hitch a ride’’ on the ribosome for cytoplasmic
degradation of p53 (Sherr andWeber, 2000), and p53 accumula-
tion after nucleolar stress was due to its failure to undergo nucle-
olus-dependent export and degradation (Rubbi and Milner,370 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc.2003). Later studies identified a direct interaction between
MDM2 and RPs in response to actinomycin D induced nucleolar
stress, providing the first potential molecular mechanism for
the nucleolar stress-p53 signaling pathway. Actinomycin D,
a commonly used drug for human cancers (da Rocha et al.,
2001), inhibits transcription catalyzed by RNA polymerases
(RNA Pol) I, II, and III at high concentrations (e.g., >30 nM), but
it selectively inhibits RNA Pol-I-dependent transcription and
hence rRNA production and ribosomal biogenesis at low
concentrations (e.g., <10 nM) (Iapalucci-Espinoza and Franze-
Fernandez, 1979; Perry and Kelley, 1970). Treating cells with
either a lower dose of actinomycin D or serum starvation inhibits
ribosome assembly and consequently releases free RPs from
the nucleolus to the nucleoplasm (Scheer and Hock, 1999). In
response to nucleolar stress induced by a low dose of actino-
mycin D (5 nM) (Dai and Lu, 2004; Dai et al., 2004; Jin et al.,
2004) and 5-Fluorouracil (Gilkes et al., 2006; Sun et al., 2007),
by serum depletion and contact inhibition (Bhat et al., 2004),
by mycophenolic acid-mediated depletion of GTP (Sun et al.,
2008), or by interfering with nucleolar function via ectopic over-
expression of nucleostemin (Dai et al., 2008), there is an
increased binding of RPL5, RPL11, and RPL23 to MDM2. This
binding inhibits MDM2’s E3 ligase function, resulting in p53
accumulation and activation. In addition to the three RPs,
RPS7 (Chen et al., 2007; Zhu et al., 2009) and RPL26 (Ofir-Rose-
nfeld et al., 2008) have also been shown to interact with MDM2.
The consequence of the RPS7-MDM2 interaction resembles that
of the aforementioned three RPs in terms of their binding to
MDM2 and activation of p53. However, surprising findings
from a latest study show that MDMX can facilitate RPS7
suppression of MDM2 and that RPS7 itself is a substrate for
MDM2 ubiquitination. Thus, it is proposed that RPS7 acts as
both effector and affector of MDM2 (Zhu et al., 2009).
The interaction of RPL26 with MDM2 appears to perform
a different function. RPL26 was found to increase the transla-
tional rate of p53 mRNA by binding to its 50 untranslated region
(Takagi et al., 2005) and, in this case, MDM2 acts as a ubiquitin
E3 ligase for ubiquitylation and degradation of RPL26, hence
inhibiting p53 translation (Ofir-Rosenfeld et al., 2008). Recently,
an RPS27-like protein (RPS27L) was identified as a direct p53
transcriptional target (He and Sun, 2007) and also thought to
activate p53 by repressing MDM2 activity (Y. Sun, personal
communication). Altogether, these findings indicate that RPs
could play a pivotal role in p53 response to nucleolar stress
(Figure 1).
Multiple Ribosomal Players
Ribosomal biogenesis consumes a major part of cellular energy
and resources and plays a key role in the life cycle of a cell (Con-
lon and Raff, 1999; Neufeld and Edgar, 1998; Warner, 1999) and
thus is strictly monitored in the cell. Previous studies have
concentrated on how changes of proliferation lead to alteration
of ribosome production (Pyronnet and Sonenberg, 2001), but
less attention has been paid to how alterations of ribosomal
biogenesis may influence cell proliferation. As discussed above,
recent studies using mammalian systems have begun to reveal
the nucleolar stress-RP-MDM2-p53 signaling pathway and to
unfold the role of this pathway in coordinating inhibition of cell
growth with cell cycle arrest.
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with cell division, both of which are very complex and sophisti-
cated cell functions, it is not surprising for the cell to use multiple
RPs to regulate the MDM2-p53 feedback loop. Why are multiple
RPs necessary? Before discussing this, it is necessary to briefly
describe MDM2’s functional domains. MDM2 contains three
conserved regions: an N-terminal p53 binding domain, a central
acidic region encompassing a C4 zinc finger, and a C-terminal
RING domain conferring the E3 ligase activity. The importance
of the central acidic region and the C4 zinc finger for mediating
MDM2 ubiquitination and degradation of p53 has been elegantly
demonstrated by a domain-swapping experiment between
MDM2 and its homolog MDMX (also known as MDM4) (Kawai
et al., 2003; Meulmeester et al., 2003). This notion is also under-
scored by the finding that ARF binds to this region to suppress
MDM2 activity (Argentini et al., 2001; Kawai et al., 2003; Meul-
meester et al., 2003). Importantly, these findings also provide
a basis for how binding of the RPs to MDM2 may interfere with
MDM2’s inhibition of p53 function.
LikeARF (Argentini et al., 2001;Kawai et al., 2003;Meulmeester
et al., 2003),RPL5,RPL11, andRPL23all bind to thecentral acidic
region of MDM2 in an apparently similar but nonidentical manner
(Dai et al., 2004). Detailed analysis of these bindings reveals that
these RPs require specific domains for efficient MDM2 binding.
For example, the MDM2 C4 zinc finger is critical for its binding
to RPL5 and RPL11, because the zinc finger mutant MDM2C305F
cannot bind either one, but is not required for RPL23 binding (Dai
et al., 2006b; Lindstrom et al., 2007b). Interestingly, a slightly
different C4 zinc finger mutant, MDM2C305S, fails to bind RPL11,
but is still capable of interacting with RPL5 and RPL23 (Gilkes
et al., 2006). Whether RPL11 binds directly to the C4 zinc finger
or whether the zinc finger only provides structural stability allow-
ingMDM2 to bind to RPL11 remains unclear. Nevertheless, these
studies suggest that the RPs, though interacting with the same
MDM2 central acidic domain, have specific sequence require-
Figure 1. Schematic of RP MDM2 p53
Pathway Regulation by Nucleolar Stress
Under normal growth conditions (no stress), small
(S; 40S) and large (L; 60S) RPs are assembled in
the nucleolus (NO) and transported to the cyto
plasm (CP) for protein synthesis. Under nucleolar
stress, ribosomal biogenesis is inhibited and ribo
some free forms of RPs (RPL and RPS) enter the
nucleoplasm (NP) to interact with MDM2, resulting
in p53 stabilization and activation. Similarly, RPs
either released from breaking down (indicated by
wavy edges) of cytoplasmic ribosomes or over
produced in the cytoplasm can enter the nucleo
plasm to interact with MDM2.
ments for binding. Surprisingly, these
MDM2-interacting RPs have not been
found to bind to MDMX (Gilkes et al.,
2006; Jin et al., 2006), implying that
fundamental structural differences exist
between MDM2 and MDMX even though
both contain a similar central acidic
domain and C4 zinc finger.
It is still puzzling why RPL11’s ability to
bind MDM2 relies so heavily on the
MDM2 C4 zinc finger. Some clues may arise from the structural
features of this domain, which belongs to a class of zinc fingers
known as RanBP2/NZF with a defined consensus sequence X(4)-
W-X-C-X(2-4)-C-X(3)-N-X(6)-C-X(2)-C-X(5), where ‘‘X’’ is any amino
acid. The NZF type of zinc finger is a compact zinc-binding
module found in many proteins that function in ubiquitin-related
processes, including direct interaction with ubiquitins (Alam
et al., 2004). The solution structure of the MDM2 C4 zinc finger
(Protein Data Bank accession number 2C6B) (Yu et al., 2006)
indeed discloses that MDM2 shares the zinc finger structure
with a wide variety of proteins that have distinct functions and
mostly involve binding other macromolecules. For instance, the
C4 zinc finger of RanBP2 binds to the nuclear export receptor
protein Crm-1 (Singh et al., 1999). Also, theC4 zinc finger domain
of some other proteins mediates binding to RNA. For example,
the zinc finger protein znf265 interacts with pre-mRNA and is
able to alter splicing patterns (Adams et al., 2001), and the zinc
finger domain of Npl4 binds to ubiquitin (Alam et al., 2004; Meyer
et al., 2002). Although the MDM2 zinc finger may not bind to
ubiquitin (Meyer et al., 2002), it could directly bind to rRNA,
mRNA, or Crm-1 and, if so, RPL11 (and other MDM2-binding
RPs) might compete with MDM2 for binding to these molecules.
Consistent with the observation that RPL11, RPL5, and RPL23
bind to overlapping yet distinct domains within the central region
of MDM2, these RPs appear to utilize similar yet nonidentical
mechanisms to regulate MDM2’s E3 ubiquitin ligase activity
(Dai et al., 2006b). Like ARF, when RPL11 is overexpressed in
cells, it suppresses p53 polyubiquitination to a lesser degree
than do RPL5 and RPL23 (Dai et al., 2006b). Also similar to
ARF, RPL11 does not inhibit ubiquitination of Mdm2, instead it
represses degradation of MDM2 via a postubiquitination mecha-
nism,whereasRPL5andRPL23suppressMDM2autoubiquitina-
tionwhencoexpressedwithMDM2 (Dai et al., 2006b).However, it
remains intangible how exactly these RPs negate MDM2’s E3
ligase activity (see more discussion in the following section).Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc. 371
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for p53’s full response to nucleolar stress. Why, then, are
multiple RPs needed to interact with MDM2 and suppress its
activity, and why does knockdown of each of the RPs attenuate,
at least partially, nucleolar stress-induced p53 activation?
Although there has not been a definitive answer thus far, it is
possible that multiple RPs might sense different growth inhibi-
tory or ribosomal stress signals so that different steps of ribo-
somal biogenesis can be effectively monitored. Also, in addition
to the aforementioned difference in their mechanisms, the amino
acid sequence in MDM2 required for RPL23 binding is different
from that for RPL11 binding, so that RPL23 and RPL11 can
bind MDM2 simultaneously to form a ternary complex (Dai
et al., 2006b; Lindstrom et al., 2007b). Consistent with this
idea, endogenous RPL23 and RPL11 appear to react differently
to actinomycin D treatment, given that the former decreased
whereas the latter increasedwhen cells were treated with actino-
mycin D (Jin et al., 2004). Moreover, multiple MDM2-binding RPs
may work together to synergize their inhibitory effects on MDM2
when an error in ribosomal biogenesis occurs, as exemplified by
the cooperation of RPL11 with RPL5 to synergistically inhibit
MDM2 and activate p53 (Horn and Vousden, 2008). This is
consistent with the finding that RPL11 and RPL5 are more
essential for p53 response to nucleolar stress than is RPL23,
given that knockdown of RPL11 or RPL5 substantially alleviates
p53 activation induced by this stress, whereas knockdown of
RPL23 actually induces p53 (Dai et al., 2004; Jin et al., 2004).
Another explanation for why multiple RPs may perform similar
functions to activate p53 could be that they may compensate
for one another or serve as rescuers if any of them fails. Because
ribosomal biogenesis is a highly coordinated process involving
a number of vital cellular activities taking place in different
subcellular compartments and involving numerous steps and
cofactors, errors could occur at each of these steps and pose
dire consequences for cells. For monitoring these steps, each
of the MDM2-interacting RPs may preferentially recognize
specific signals of nucleolar stresses. In partial agreement with
this hypothesis, knockdown of RPS6 impairs 40S ribosomal
biogenesis, promotes the translation of RPL11 mRNA specifi-
cally, and subsequently initiates RPL11-dependent MDM2 inhi-
bition and p53 activation (Fumagalli et al., 2009). In summary,
for cells to grow and proliferate normally, multiple RPs appear
to be needed to signal to the p53 pathway in response to a variety
of nucleolar stresses (Figure 1).
How Do the Ribosomal Players Work?
If multiple RPs are needed to sense and transduce nucleolar
stress to the MDM2-p53 pathway, then how do they work?
Where do the RPs find and bind to MDM2, given that RPs mostly
reside in the nucleolus and the cytoplasm, whereas MDM2 often
stays in the nucleoplasm? One possibility is that the RPs may
interact with MDM2 in the nucleoplasm on their way to the nucle-
olus because they, once translated in the cytoplasm, must be
transported through the nucleoplasm to the nucleolus for ribo-
some assembly. An increase in RP translation would lead to
increased traffic of the RPs through the nucleus, consequently
an increased interaction with MDM2. In this regard, the RP-
MDM2 interaction could function as a mechanism sensing
elevated RP translation, such as the increase in global translation372 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc.caused by overexpression of the proto-oncogene c-Myc
(Schmidt, 2004) or the rise of RPL11 level by RPS6 knockdown
(Fumagalli et al., 2009). It could also sense the breakdown of
cytoplasmic polysomes and the resulting release of individual
ribosomal RPs into the nucleoplasm (Dai et al., 2004; Gilkes
et al., 2006; Jin et al., 2004). Alternatively, given that there is
not a physical boundary between the nucleoplasm and the
nucleolus, RPs and other nucleolar proteins could shuttle freely
between the two cellular compartments (Chen and Huang,
2001), and such an ability would provide an opportunity for
excess RPs to interact with MDM2 in the nucleoplasm. In
a similar and reciprocal way, MDM2 may enter the nucleolus,
as can be seen after cells treated by MG132 (Klibanov et al.,
2001), presumably through its interaction with the nucleolar
ARF (Tao and Levine, 1999;Weber et al., 1999), and thus interact
with RPs in the nucleolus (Lohrum et al., 2003). However, the
latter mechanism might be context specific, given that MDM2
was not detected in the nucleolus under unstressed or nucle-
olar-stress conditions in recent studies (Dai et al., 2008; Sun
et al., 2008).
Another quandary regarding how RPs regulate MDM2
concerns protein levels in a cell. Unlike DNAdamage- or aberrant
oncogene-induced p53 activation, which often requires either
activation of a kinase (checkpoint kinases) or induction of
a protein (the tumor suppressor ARF) that is usually maintained
at basal levels under unstressed conditions, RPs are always
abundant in cells. Then, how is the RP-MDM2 interaction pre-
vented under normal and favorable growth conditions, yet
promoted in response to nucleolar stress? It is conceivable
that without stress, an appropriate amount of RPs is produced
just for the need of ribosome assembly, but any excess of RPs
beyond this demand undergo constant degradation (Lam et al.,
2007). However, under nucleolar stress, rRNA synthesis is
reduced or blocked and extra ribosome-unbound RPL11 trans-
locates to the nucleoplasm to interact with MDM2 and activate
p53 (Bhat et al., 2004), even though the total amount of RPs is
not altered.
As discussed above, like ARF, all MDM2-binding RPs inhibit
the MDM2 ubiquitin ligase activity by binding to its central acidic
domain. However, it is unclear how exactly the binding of these
small inhibitory proteins in themiddle ofMDM2 leads to inhibition
of the ubiquitin ligase activity of its C-terminal RING finger. One
possible explanation is that the central acidic domain of MDM2
acts as a flexible arm to juxtapose the N-terminal-bound p53
within close proximity of the C-terminal RING domain in order
to facilitate ubiquitin transfer. The binding of RPL11 or other
small protein molecules to the MDM2 central domain may
reduce its flexibility, and the rigid MDM2 is thus unable to bring
its RING domain and p53 together. Although this prediction is
tempting, direct evidence is lacking and a better mechanistic
insight will come from a 3D structure of the complex of MDM2
with RPL11 or other RPs.
Another possible mechanism by which RPs inhibit MDM2’s E3
ligase activity concerns the MDM2 homolog MDMX. Previous
studies using protein overexpression and siRNA knockdown
suggested that MDMX enhances the MDM2 E3 ligase activity
(Linares et al., 2003). A later study showed that MDMX-deficient
MEF cells (Mdm2+/; MdmX/) had a moderately elevated level
of endogenous p53 compared to that in MDMX-proficient cells
Cancer Cell
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MDMX may contribute to p53 degradation in vivo. Although
howMDMX contributes to MDM2’s E3 activity remains obscure,
it is clear that MDMX is essential for negating p53 function as
germline inactivation of Mdmx results in embryonic lethality
that can be rescued by concomitant deletion of p53 (Migliorini
et al., 2002; Parant et al., 2001). The RING finger domain of
MDMX is crucial for MDM2-mediated p53 degradation (Poyurov-
sky et al., 2007; Uldrijan et al., 2007), probably by facilitating het-
erodimerization with MDM2 (Jackson and Berberich, 2000;
Sharp et al., 1999; Stad et al., 2000; Tanimura et al., 1999).
Hence, it is possible that RPs (probably ARF as well) might inhibit
MDM2 function by disrupting the MDM2-MDMX interaction.
Alternatively, RPL11 can promoteMDMXdegradation by binding
toMDM2, consequently activating p53, given that it fails to do so
when the RPL11 binding-deficient MDM2C305S mutant is used
(Gilkes et al., 2006).
In addition to mediating p53 ubiquitination, the C-terminal
RING domain of MDM2 is shown to be the E3, at least in vitro,
for its own ubiquitination and degradation (Fang et al., 2000;
Honda and Yasuda, 2000). However, even though ectopic
RPL11 can inhibit MDM2-mediated p53 ubiquitination, it does
not inhibit MDM2 autoubiquitination (Dai et al., 2006b), just like
ARF (Xirodimas et al., 2001). Thus, it appears that these two
small proteins preferentially inhibit MDM2’s E3 activity toward
p53 but not its autoubiquitination. This could be explained by
the existence of a putative cellular E3 ligases for MDM2, given
that in vivo MDM2 bearing a C462A mutation in its C-terminal
RING domain, which abolishes its E3 ligase activity, is still ubiq-
uitinated and degraded as quickly as wild-type MDM2 under
both unstressed and genotoxically stressed conditions (Itahana
et al., 2007). Such a result could also explain why RPL11 or ARF
do not inhibit MDM2 ‘‘autoubiquitination’’ (Dai et al., 2006b).
Relevance to Cancer and Other Genetic Diseases
Identification of several RPs as crucial players in regulating p53
function not only reveals molecular insight into this underappre-
ciated signaling pathway but also raises new questions con-
cerning the importance of RPs in cancer prevention and
development. The role of RPs and ribosomal biogenesis in
tumorigenesis has been regarded as a double-edged sword.
On one hand, elevated levels of ribosomal biogenesis and
protein translation, such as from overexpression of eIF-4E (Rug-
gero et al., 2004; Wendel et al., 2004) and tRNAs and 5S rRNA
(Marshall et al., 2008), have been linked to tumor formation in
multiple mouse tissues (reviewed by Dai and Lu, 2008; Ruggero
and Pandolfi, 2003). For example, overexpression of RPS3a can
lead to transformation and tumorigenesis in nude mice (Naora
et al., 1998). On the other hand, reduction of ribosomal biogen-
esis and translational capacity due to genetic hapoloinsuffi-
ciency, such as loss of one copy of an RP-encoding gene or
mutation of a gene essential for ribosomal biogenesis, has
been associated with a high incidence of cancer development
in humans. For instance, mutation of the DKC1 gene, whose
protein product dyskerin is a putative pseudouridine synthase
important for pre-rRNA processing, is tightly linked to dyskerato-
sis congenital disease with characteristics of premature aging
and an increased susceptibility to certain cancers (Ruggero
et al., 2003). Also, RMRP, encoding an RNase vital for pre-rRNA processing, is mutated in the pleiotropic human disease
cartilage-hair hypoplasia, which typically results in short stature,
defective cellular immunity, and predisposition to cancer (Ridan-
paa et al., 2001).
Mutations in several RPs have also been linked to cancer-
prone genetic diseases. A prominent example is Diamond-
Blackfan anemia (DBA), an inheritable disease initially found to
be associated with mutation of RPS19. Heterozygous null muta-
tions of RPS19 were found in 25% of DBA patients (Draptchin-
skaia et al., 1999), who often suffer from chronic constitutional
regenerative anemia, various degrees of congenital abnormali-
ties, and an increased susceptibility to hematopoietic malignan-
cies. Another RP-associated disease is 5q syndrome, which is
frequently linkedwith deletion of one allele ofRPS14 and charac-
terized by increased incidence of hematopoietic tumors and
anemia (Ebert et al., 2008). Remarkably, recent studies have
found various heterozygous mutations, including single point
mutations, in RPL5, RPL11, and RPS7 in DBA patients (Cmejla
et al., 2009; Gazda et al., 2008).Mutational screening in zebrafish
has also revealed that a number of RP genes are cancer related
(Amsterdam et al., 2004) and mutations of these genes in zebra-
fish are linked with growth impairment and predisposition to
tumorigenesis (Lai et al., 2009). Although it is still unknown how
mutations in the RPs result in DBA and cancer, the fact that
RPL5, RPL11, and RPS7, three RPs mutated in DBA (Gazda
et al., 2008), are all MDM2-binding proteins cannot be regarded
as coincidence.
In addition to the association of RP mutants with DBA and
cancer, mutations in RPS19 or RPS20 are also tied with a p53-
mediated dark skin effect in mice (McGowan et al., 2008). It is
perplexing how the reduction of a specific RP can cause a tissue-
and cell-specific pathological phenotype. The pathological
changes may result from global decline of ribosomal biogenesis
owing to loss of one copy of an rp gene and subsequent diminu-
tion of translation (Ellis and Lipton, 2008; Liu and Ellis, 2006). It is
also speculated that some of these diseases can be explained by
RPL11-mediated deregulation of c-Myc, an important player in
ribosomal biogenesis (Dai et al., 2007). A testable hypothesis is
that haploinsufficiency of certain RPs could reduce the produc-
tion of tumor suppressors, such as p53 (MacInnes et al., 2008),
and hence render DBA patients more susceptible to tumorigen-
esis. Finally, it is postulated that the high incidence of malignan-
cies in the RP-pertinent diseases could be a result of a defect in
the p53 pathway. As discussed above, several RPs including
RPL11, RPL5, RPL23, and RPS7 can activate p53 by attenuating
MDM2 function in response to stresses derived from ribosomal
malfunction. Hence, it is possible that reduced expression of
some RPs could impede stress-induced p53 activation due to
their decreased MDM2 interaction.
Questions and Prospects
Althoughaccumulating evidence hasbegun todivulge a relatively
new signaling pathway linking defects in ribosomal biogenesis
with p53, suggesting another cellular surveillance mechanism
for cancer prevention, more questions than answers are brought
up by these studies. (1) Why are multiple RPs needed to signal to
p53? So far, there are at least four confirmed RPs that bind to the
central acidic domain of MDM2 and use apparently similar
mechanisms to activate p53. Do multiple RPs have redundantCancer Cell 16, November 3, 2009 ª2009 Elsevier Inc. 373
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Reviewroles, inhibiting MDM2 in response to the same type of stress?
Or, do they have specific roles in sensing different types of
stress? (2) What are the physiological stresses that activate the
RP-p53 signaling pathway? Would cancer develop if this
pathway were impaired? Amousemodel that specifically targets
this pathway is crucial for understanding the physiological role of
the RP-MDM2 interaction. (3) Does Mdm2 have a general role in
regulating RP turnover, like that shown for RPL26 and RPS7
(Ofir-Rosenfeld et al., 2008; Zhu et al., 2009)? If so, would this
explain MDM2 overexpression-induced growth inhibition? (4)
Do the MDM2-interacting RPs signal to p53 in response to
rRNA damage? rRNAs are the most actively synthesized nucleic
acid species in a cell, highly abundant and essential for cell
growth and proliferation (Neufeld and Edgar, 1998; Warner,
1999). Thus, rRNA is vulnerable to both endogenous and exoge-
nous genotoxic agents. A recent study showed that yeast uses
similar mechanisms to repair genotoxic damage to both DNA
and rRNA molecules (Fujii et al., 2009). How the integrity of
rRNA is monitored during ribosomal biogenesis is not clear,
nor do we know how p53 may sense rRNA damage. (5) Are
anyRPsmutated in human cancers? As discussed above, muta-
tions in RPL5 and RPL11 are associated with DBA (Cmejla et al.,
2009; Gazda et al., 2008). Reports of direct connections between
mutations in the p53-activating RPs and cancer, however, have
been lacking. It is possible that these RPs may play a role in
cancer in a manner similar to the so-called nononcogene addic-
tion (NOA) molecules (Luo et al., 2009; Solimini et al., 2007).
Unlike oncoproteins, such as H-Ras or c-Myc that are often
mutated in human cancers, NOA proteins are rarely mutated in
human cancers. However, like oncoproteins, NOA proteins are
required for cancer cell growth. Under normal growth conditions,
the p53-activating RPs are essential components of ribosome
biogenesis. Under stress conditions, their intrinsic antitumor
activities are awakened (Figure 1). Examples of other proteins
that are crucial for p53 activation but are not normally mutated
in cancers include Chk1, Chk2, p300, and CBP. The intrinsic
antitumor activities of these molecules could be useful for anti-
cancer drug discovery (Luo et al., 2009).
Indeed, identification of MDM2-RP interactions offers an
opportunity for anticancer drug development. MDM2 is highly
expressed in various human cancers, including breast cancer,
sarcoma, glioma, and blood cancers (reviewed in Onel and
Cordon-Cardo, 2004).MDM2 is amplified in 50% of leukemias
and lymphomas, in which TP53 mutations are rare (Bueso-
Ramos et al., 1996). Hence, MDM2 could be an ideal target for
anticancer drugs. The previous focus of anti-MDM2 drug
screening has been on either the N-terminal p53-binding domain
(Issaeva et al., 2004; Shangary et al., 2008; Vassilev et al., 2004)
or the C-terminal RING-finger E3 ubiquitin ligase domain (Yang
et al., 2005) of MDM2. The MDM2 central acidic domain,
including the zinc finger, is crucial for MDM2-induced p53
ubiquitination and degradation (Kawai et al., 2003). The interac-
tion of ARF and RPs with this MDM2 domain suppresses
MDM2’s E3 activity and activates p53. Thus, the central domain
represents another targeting site in MDM2 for anticancer
drug screening. Future efforts should be taken to identify small
molecules that inhibit MDM2 activity by directly binding to
its central domain. Gaining promising candidates from this
attempt will not only shed light on the biological significance of374 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc.RP-MDM2-p53 interplay but also provide potential drugs for
therapeutic intervention of cancers that harbor wild-type p53
and high levels of MDM2.
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